ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Sanofi's Sarclisa Secures FDA Approval For First-Line ... - Benzinga
WEB2 days ago · Sarclisa is the first anti-CD38 therapy in combination with SoC VRd to reduce disease progression or death by 40% vs. VRd alone. At a median follow-up of 59.7 months, the median PFS with the ...
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEB4 days ago · Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not ...
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune ...
WEBJun 19, 2024 · In this study, anti-CD38 targeted therapy rapidly boosted platelet levels by inhibiting antibody-dependent cell-mediated cytotoxicity on platelets, maintained long-term efficacy by clearing...
Sarclisa approved in the US as the first anti-CD38 therapy
WEB2 days ago · Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not eligible for transplant. “Multiple myeloma is most frequently diagnosed in patients 65 years and older, yet the options for treatment in this population ...
CD38 — a new target in renal immune disease - Nature
WEBJul 23, 2024 · The high expression of CD38 in specific subsets of haematopoietic malignancies and plasma B cell tumours, such as multiple myeloma, has catalysed the development of therapeutic anti-CD38...
Real world data on outcomes of anti-CD38 antibody treated
WEBDec 8, 2023 · Recent therapeutics targeting the B-cell maturation antigen (BCMA) have shown promising efficacy in refractory patient populations; the United States Food and Drug Administration has recently ...
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for …
WEBJun 3, 2024 · Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal...
WEBIn this study, anti-CD38 targeted therapy rapidly boosted platelet levels by inhibit-ing antibody-dependent cell-mediated cytotoxicity on platelets, maintained long-term efficacy by...
talquetamab-tgvs for relapsed or refractory multiple myeloma
WEBOn August 9, 2023, the Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with relapsed or refractory multiple myeloma who have...
Skip to content